Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04642404 · ClinicalTrials.gov registry record · Phase 1
CBD for Dental Pain
A Phase 1 study of Toothache and Odontalgia, sponsored by The University of Texas Health Science Center at San Antonio.
- Completed
- Registry status
- Phase 1
- Development phase
- 64
- Enrollment target
- 1
- Study location
NCT04642404: Completed Phase 1 study of Toothache and Odontalgia, sponsored by The University of Texas Health Science Center at San Antonio.
NCT04642404 is a Phase 1 study of Toothache and Odontalgia that has completed, run by The University of Texas Health Science Center at San Antonio. The registered enrollment target is 64 participants, below the 143-participant average among 3 other Toothache trials with a reported enrollment target (55% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04642404, a Phase 1 study of Toothache and Odontalgia, has completed, sponsored by The University of Texas Health Science Center at San Antonio.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 64 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaulate CBD as a therapeutic approach for dental pain. Eligible subjects presented with emergency dental pain will be give a single dose of Epidiolex (FDA-approved CBD) or placebo and will be monitored for 3 hours for pain symptoms and psychologic effects.
Primary Outcome
Patients will report their pain level using a 100mm Visual Analogue Scale at baseline, measured at baseline and 180 minutes. Score is measured on a 100mm scale, scored 0-100, with a lower score indicating less pain.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Epidiolex 100 mg/mL Oral Solution
Study Locations (1)
Texas
- The University of Texas Health Science Center at San Antonio - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2021-03-01 |
| Est. Completion | 2023-03-13 |
| Phase | Phase 1 |
What the finished NCT04642404 record still lists
NCT04642404 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 64 participants, a relatively small participant target, below the 143-participant average among 3 other Toothache trials with a reported enrollment target (55% lower).
The record links to 2 conditions, with Toothache appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04642404 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT04642404 about?
NCT04642404 is a clinical study titled "CBD for Dental Pain". The purpose of this study is to evaulate CBD as a therapeutic approach for dental pain. Eligible subjects presented with emergency dental pain will be give a single dose of Epidiolex (FDA-approved CBD) or placebo and will be monitored for 3 hours for pain symptoms and psychologic effects.
What is the current status of trial NCT04642404?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 64 participants. The study started on 2021-03-01. Estimated completion is 2023-03-13.
What conditions does trial NCT04642404 study?
This clinical trial studies the following conditions: Toothache, Odontalgia.
What interventions are being tested in trial NCT04642404?
The interventions under investigation include: Placebo (DRUG), Epidiolex 100 mg/mL Oral Solution (DRUG).
Who is sponsoring clinical trial NCT04642404?
This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04642404 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Toothache
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01853631 · 64 participants · Phase 1
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
- NCT03739502 · 64 participants · Phase 2
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
- NCT03739814 · 64 participants · Phase 2
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- NCT03866408 · 64 participants · Early Phase 1
Insulin Regulation of Lipolysis and Lipolysis Proteins
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI